Heart Failure With Preserved Ejection Fraction Clinical Trials in New York, New York

6 studies are recruiting for heart failure with preserved ejection fraction in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

   This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection frac…

   Stage

   Phase 3

   Ages

   18 to 99

   Site

   Icahn School of Medicine at Mount Sinai, New York, New York

   Locations

   657 in total

   Run by

   Amgen

   See if you can join NCT07037459 on ClinicalTrials.gov

2. A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)

   This is a Phase 2 placebo-controlled study to evaluate the safety and tolerability of different doses of EDG-15400 in adults with heart failure with preserved ejection fraction (HFpEF).

   Stage

   Phase 2

   Ages

   30 to 84

   Site

   Local Institution - 154, New York, New York

   Locations

   25 in total

   Run by

   Edgewise Therapeutics, Inc.

   See if you can join NCT07795814 on ClinicalTrials.gov

3. Incretin Therapies in Obesity-related HFpEF

   The central hypothesis to be tested is that patients with obesity and heart failure with preserved ejection fraction (HFpEF) prescribed tirzepatide will demonstrate reductions in measured plasma volume. In conjunction with state-of-the-art body composition analysis and measures of adipokines, this …

   Stage

   Phase 4

   Ages

   40 and older

   Site

   Columbia University Irving Medical Center (CUIMC) / NewYork Presbyterian Hospital (NYP), New York, New York

   Run by

   Columbia University

   See if you can join NCT07554638 on ClinicalTrials.gov

4. A Preliminary Study for INFORMED

   Investigators will determine whether N-of-1 trials, as a pragmatic, participant-centered approach to medication optimization that can overcome key barriers of deprescribing, can lead to increased participant confidence regarding their preference to continue or discontinue beta-blockers in older adu…

   Stage

   Phase 4

   Ages

   65 and older

   Site

   Weill Cornell Medicine, New York, New York

   Run by

   Weill Medical College of Cornell University

   See if you can join NCT05585125 on ClinicalTrials.gov

5. Assessment of CCM in HF With Higher Ejection Fraction

   The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Weill Cornell Medicine, New York, New York

   Locations

   105 in total

   Run by

   Impulse Dynamics

   See if you can join NCT05064709 on ClinicalTrials.gov

6. Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction

   Heart failure with preserved ejection fraction (HFPEF) is common and deadly but without therapy. Inconclusive studies such as TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) suggest spironolactone may be effective in HFPEF, but it is generic and will no…

   Stage

   Phase 3

   Ages

   50 to 99

   Site

   Mount Sinai Medical Cente, New York, New York

   Locations

   78 in total

   Run by

   Uppsala University

   See if you can join NCT02901184 on ClinicalTrials.gov